384 related articles for article (PubMed ID: 27354468)
1. BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression.
Barras D; Missiaglia E; Wirapati P; Sieber OM; Jorissen RN; Love C; Molloy PL; Jones IT; McLaughlin S; Gibbs P; Guinney J; Simon IM; Roth AD; Bosman FT; Tejpar S; Delorenzi M
Clin Cancer Res; 2017 Jan; 23(1):104-115. PubMed ID: 27354468
[TBL] [Abstract][Full Text] [Related]
2. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
3. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
Klempner SJ; Gershenhorn B; Tran P; Lee TK; Erlander MG; Gowen K; Schrock AB; Morosini D; Ross JS; Miller VA; Stephens PJ; Ou SH; Ali SM
Cancer Discov; 2016 Jun; 6(6):594-600. PubMed ID: 27048246
[TBL] [Abstract][Full Text] [Related]
4. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.
Tie J; Gibbs P; Lipton L; Christie M; Jorissen RN; Burgess AW; Croxford M; Jones I; Langland R; Kosmider S; McKay D; Bollag G; Nolop K; Sieber OM; Desai J
Int J Cancer; 2011 May; 128(9):2075-84. PubMed ID: 20635392
[TBL] [Abstract][Full Text] [Related]
5. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
[TBL] [Abstract][Full Text] [Related]
6. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
[TBL] [Abstract][Full Text] [Related]
7. Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations.
Kim IJ; Kang HC; Jang SG; Kim K; Ahn SA; Yoon HJ; Yoon SN; Park JG
Carcinogenesis; 2006 Mar; 27(3):392-404. PubMed ID: 16219636
[TBL] [Abstract][Full Text] [Related]
8. Methylation and expression of the tumour suppressor, PRDM5, in colorectal cancer and polyp subgroups.
Bond CE; Bettington ML; Pearson SA; McKeone DM; Leggett BA; Whitehall VL
BMC Cancer; 2015 Jan; 15():20. PubMed ID: 25613750
[TBL] [Abstract][Full Text] [Related]
9. Co-existence of BRAF V600E Gene Mutation in Tumor and Non-tumoral Surrounding Tissues in Colorectal Cancer.
Öztürk T; Toptaş-Hekimoğlu B; Eronat AP; Saygili N; Dağlar-Aday A; Başsüllü N; Türkmen I; Aydoğan HY; Bülbül G; Göksel S; Öztürk O; Isbir T
In Vivo; 2015; 29(5):577-84. PubMed ID: 26359417
[TBL] [Abstract][Full Text] [Related]
10. Class 1, 2, and 3
Schirripa M; Biason P; Lonardi S; Pella N; Pino MS; Urbano F; Antoniotti C; Cremolini C; Corallo S; Pietrantonio F; Gelsomino F; Cascinu S; Orlandi A; Munari G; Malapelle U; Saggio S; Fontanini G; Rugge M; Mescoli C; Lazzi S; Reggiani Bonetti L; Lanza G; Dei Tos AP; De Maglio G; Martini M; Bergamo F; Zagonel V; Loupakis F; Fassan M
Clin Cancer Res; 2019 Jul; 25(13):3954-3961. PubMed ID: 30967421
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.
Nakaji Y; Oki E; Nakanishi R; Ando K; Sugiyama M; Nakashima Y; Yamashita N; Saeki H; Oda Y; Maehara Y
J Cancer Res Clin Oncol; 2017 Jan; 143(1):151-160. PubMed ID: 27672042
[TBL] [Abstract][Full Text] [Related]
12.
Middleton G; Yang Y; Campbell CD; André T; Atreya CE; Schellens JHM; Yoshino T; Bendell JC; Hollebecque A; McRee AJ; Siena S; Gordon MS; Tabernero J; Yaeger R; O'Dwyer PJ; De Vos F; Van Cutsem E; Millholland JM; Brase JC; Rangwala F; Gasal E; Corcoran RB
Clin Cancer Res; 2020 Jun; 26(11):2466-2476. PubMed ID: 32047001
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.
Adackapara CA; Sholl LM; Barletta JA; Hornick JL
Histopathology; 2013 Aug; 63(2):187-93. PubMed ID: 23763264
[TBL] [Abstract][Full Text] [Related]
14. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.
Sadlecki P; Walentowicz P; Bodnar M; Marszalek A; Grabiec M; Walentowicz-Sadlecka M
Tumour Biol; 2017 May; 39(5):1010428317706230. PubMed ID: 28488545
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
16. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.
Zlobec I; Kovac M; Erzberger P; Molinari F; Bihl MP; Rufle A; Foerster A; Frattini M; Terracciano L; Heinimann K; Lugli A
Int J Cancer; 2010 Dec; 127(11):2569-75. PubMed ID: 20162668
[TBL] [Abstract][Full Text] [Related]
17. p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers.
Bond CE; Umapathy A; Ramsnes I; Greco SA; Zhen Zhao Z; Mallitt KA; Buttenshaw RL; Montgomery GW; Leggett BA; Whitehall VL
Int J Cancer; 2012 Apr; 130(7):1567-76. PubMed ID: 21557216
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
[TBL] [Abstract][Full Text] [Related]
19. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
[TBL] [Abstract][Full Text] [Related]
20. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis.
Minoo P; Moyer MP; Jass JR
J Pathol; 2007 Jun; 212(2):124-33. PubMed ID: 17427169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
